Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Gabriele Capurso

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0019-8753; OpenAlex author ID A5085191511. Sources: OpenAlex.

Their work

Papers
111 (first author 9, last author 26)
Trials
0
Grants
0
Labs led
2
Collaborators
270
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: 4 papers · 2016: 5 papers · 2017: 5 papers · 2018: 6 papers · 2019: 11 papers · 2020: 11 papers · 2021: 13 papers · 2022: 6 papers · 2023: 12 papers · 2024: 10 papers · 2025: 12 papers · 2026: 11 papers

Papers 50 of 111

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. First author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Last author DOI 10.1002/ueg2.70179↗
  3. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  4. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Last author DOI 10.1016/j.clnu.2025.106573↗
  5. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. First author DOI 10.1016/j.dld.2026.02.015↗
  6. Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants. Co-author DOI 10.1016/j.dld.2026.02.020↗
  7. The future of integrated treatment for PDAC: Learning from the past, advancing for the better. Last author DOI 10.1016/j.dld.2026.09.002↗
  8. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  9. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2026.04.005↗
  10. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  11. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  12. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  13. Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort. Co-author DOI 10.1002/ueg2.70102↗
  14. The exposome as a target for primary prevention and a tool for early detection of pancreatic cancer. Last author DOI 10.1016/j.bpg.2025.101991↗
  15. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Last author DOI 10.1016/j.dld.2024.05.017↗
  16. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Last author DOI 10.1016/j.dld.2025.03.009↗
  17. Author's Reply: Comment on "Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer". Last author DOI 10.1016/j.dld.2025.06.006↗
  18. Author's reply: "Comment on "Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Last author DOI 10.1016/j.dld.2025.08.085↗
  19. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2024.12.005↗
  20. Gastrointestinal symptoms in the journey of pancreatic cancer patients. Last author DOI 10.1080/14737140.2025.2517888↗
  21. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  22. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  23. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  24. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  25. Management of malignant Gastric Outlet Obstruction (mGOO) due to pancreatic cancer in the era of EUS-Gastrojejunostomy: an international practice survey and ca… Co-author DOI 10.1007/s00464-024-10803-0↗
  26. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Co-author DOI 10.1007/s10689-024-00366-3↗
  27. Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.10.015↗
  28. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  29. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Last author DOI 10.1016/j.pan.2024.02.008↗
  30. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  31. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Last author DOI 10.1097/sla.0000000000006094↗
  32. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  33. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. First author DOI 10.14309/ajg.0000000000002546↗
  34. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  35. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  36. Cost–effectiveness of pancreatic cancer screening: Time for a more tailored approach First author DOI 10.1002/ueg2.12380↗
  37. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  38. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  39. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  40. European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019. Co-author DOI 10.1016/j.pan.2023.09.001↗
  41. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  42. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  43. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  44. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  45. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  46. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  47. The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771↗
  48. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Co-author DOI 10.3390/cancers14246130↗
  49. Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v28.i10.976↗
  50. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Co-author DOI 10.4103/eus-d-21-00111↗

Closest collaborators

The 25 strongest of 270 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paolo Giorgio Arcidiacono · 34 shared papers, 2019–2026 · strength 6.25
  2. Massimo Falconi · 36 shared papers, 2019–2026 · strength 5.90
  3. Lívia Archibugi · 36 shared papers, 2015–2026 · strength 5.46
  4. Michele Reni · 22 shared papers, 2019–2026 · strength 3.80
  5. Gaetano Lauri · 7 shared papers, 2023–2026 · strength 1.94
  6. Stefano Crippa · 11 shared papers, 2019–2026 · strength 1.85
  7. Ruggero Ponz de Leon Pisani · 7 shared papers, 2022–2026 · strength 1.68
  8. Daniele Campa · 16 shared papers, 2013–2025 · strength 1.67
  9. Giuseppe Vanella · 10 shared papers, 2020–2026 · strength 1.60
  10. Maria Chiara Petrone · 11 shared papers, 2019–2026 · strength 1.57
  11. Marina Macchini · 8 shared papers, 2022–2026 · strength 1.51
  12. Giulia Orsi · 8 shared papers, 2021–2026 · strength 1.42
  13. Federico Canzian · 15 shared papers, 2013–2025 · strength 1.42
  14. Salvatore Paiella · 8 shared papers, 2019–2026 · strength 1.32
  15. Manuel Gentiluomo · 8 shared papers, 2019–2025 · strength 1.12
  16. Matteo Tacelli · 5 shared papers, 2022–2026 · strength 1.09
  17. Erica Secchettin · 6 shared papers, 2020–2026 · strength 1.03
  18. Gemma Rossi · 7 shared papers, 2020–2026 · strength 1.01
  19. Domenico Tamburrino · 6 shared papers, 2020–2026 · strength 0.99
  20. Francesco DE COBELLI · 7 shared papers, 2020–2026 · strength 0.96
  21. Giulia Martina Cavestro · 8 shared papers, 2019–2026 · strength 0.94
  22. Claudio Doglioni · 7 shared papers, 2019–2024 · strength 0.93
  23. Sabrina Gloria Giulia Testoni · 8 shared papers, 2019–2023 · strength 0.91
  24. Raffaele Pezzilli · 12 shared papers, 2013–2024 · strength 0.86
  25. Claudio Sette · 8 shared papers, 2013–2024 · strength 0.85

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.